The KMO allele encoding Arg 452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression

Molecular Psychiatry

Volumn 19, Issue 3, 2014, Pages 334-341

  Lavebratt, C ^a   Olsson, S ^b   Backlund, L ^b   Frisen L ^a,b   Sellgren, C ^b   Priebe, L ^c   Nikamo, P ^a,b   Traskman Bendz L ^d   Cichon, S ^c,e   Vawter, M P ^f   Osby U ^a,g   Engberg, G ^b   Landen M ^b,h   Erhardt, S ^b   Schalling, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF BONN   (Germany)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e FORSCHUNGSZENTRUM JÜLICH   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Tiohundra AB ^*  (Sweden)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Gene expression; Genetic variation; Kynurenic acid; Kynurenine pathway; Prefrontal cortex; Psychosis

Indexed keywords

ADULT; AGED; ALLELES; BIPOLAR DISORDER; CASE-CONTROL STUDIES; CELL LINE; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HIPPOCAMPUS; HUMANS; KYNURENIC ACID; KYNURENINE 3-MONOOXYGENASE; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; YOUNG ADULT;

ARGININE; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE; MESSENGER RNA;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR DISORDER TYPE 1; CEREBROSPINAL FLUID LEVEL; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MALE; MANIA; ONSET AGE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS;

EID: 84894560873     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.11     Document Type: Article

References (70)

1. Goldberg JF, Chengappa KN. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord 2009; 11(Suppl 2): 123-137
2. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: Evidence from a meta-Analysis of twin studies. Arch Gen Psychiatry 2003; 60: 1187-1192
3. Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: Dissecting psychosis. J Med Genet 2005; 42: 193-204
4. Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet 2009; 373: 234-239
5. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963; 20: 140-144
6. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J Clin Psychiatry 2009; 70: 1078-1090
7. Söderlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S et al. Elevation of cerebrospinal fluid interleukin-1beta in bipolar disorder. J Psychiatry Neurosci 2011; 36: 114-118
8. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ et al. Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection. J Neurochem 2001; 78: 842-853
9. Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V et al. Characterization of the kynurenine pathway in human neurons. J Neurosci 2007; 27: 12884-12892
10. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-477
11. Ganong AH, Cotman CW. Kynurenic acid and quinolinic acid act at N-methyl-Daspartate receptors in the rat hippocampus. J Pharmacol Exp Ther 1986; 236: 293-299
12. Birch PJ, Grossman CJ, Hayes AG. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 1988; 154: 85-87
13. Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-Aspartic acid receptors: Characterization and identification of a new class of antagonists. J Neurochem 1989; 52: 1319-1328
14. Parsons CG, Danyschizophrenia W, Quack G, Hartmann S, Lorenz B, Wollenburg C et al. Novel systemically active antagonists of the glycine site of the N-methyl-Daspartate receptor: Electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 1997; 283: 1264-1275
15. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-Alpha7 nicotinic receptor expression: Physiopathological implications. J Neurosci 2001; 21: 7463-7473
16. Linderholm K, Powell S, Olsson E, Holtze M, Snodgrass R, Erhardt S. Role of the NMDA-receptor in Prepulse Inhibition in the Rat. Int J Tryptophan Res 2010; 3: 1-12
17. Erhardt S, Engberg G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 2002; 175: 45-53
18. Nilsson LK, Linderholm KR, Erhardt S. Subchronic treatment with kynurenine and probenecid: Effects on prepulse inhibition and firing of midbrain dopamine neurons. J Neural Transm 2006; 113: 557-571
19. Olsson SK, Andersson AS, Linderholm KR, Holtze M, Nilsson-Todd LK, Schwieler L et al. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: Implications for schizophrenia. Int J Neuropsychopharmacol 2009; 12: 501-512
20. Shepard PD, Joy B, Clerkin L, Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 2003; 28: 1454-1462
21. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 2004; 56: 255-260
22. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007; 33: 797-804
23. Olsson SK, Samuelsson M, Saetre P, Lindström L, Jönsson EG, Nordin C et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci 2010; 35: 195-199
24. Erhardt S, Öberg H, Mathe JM, Engberg G. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 2001a; 20: 353-362
25. Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005; 80: 315-322
26. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001b; 313: 96-98
27. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-530
28. Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 2011; 37: 1147-1156
29. Olsson SK, Sellgren C, Engberg G, Landén M, Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar disorder type I. Bipolar Dis 2012; 14: 719-726
30. Nilsson LK, Nordin C, Jonsson EG, Engberg G, Linderholm KR, Erhardt S. Cerebrospinal fluid kynurenic acid in male and female controls - correlation with monoamine metabolites and influences of confounding factors. J Psychiatr Res 2007; 41: 144-151
31. Nilsson-Todd LK, Nordin C, Jönsson EG, Skogh E, Erhardt S. Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. Acta Neuropsychiatrica 2007; 19: 45-52
32. Moroni F. Tryptophan metabolism and brain function: Focus on kynurenine and other indole metabolites. Eur J Pharmacol 1999; 375: 87-100
33. Moroni F, Russi P, Gallo-Mezo MA, Moneti G, Pellicciari R. Modulation of quinolinic and kynurenic acid content in the rat brain: Effects of endotoxins and nicotinylalanine. J Neurochem 1991; 57: 1630-1635
34. Connick J, Heywood GC, Sills GJ, Thomson GG, Brodie MJ, Stone TW. Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen Pharmacol 1992; 23: 235-239
35. Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, Moroni F. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J Neurochem 1995; 65: 1176-1183
36. Speciale C, Wu HQ, Cini M, Marconi M, Varasi M, Schwarcz R. (R, S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol 1996; 315: 263-267
37. Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011; 68: 665-674
38. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The stanley foundation brain collection and neuropathology consortium. Schizophr Res 2000; 44: 151-155
39. Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ et al. Meta-Analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci 2007; 31: 221-243
40. Backlund L, Nikamo P, Hukic DS, Ek IR, Tra?skman-Bendz L, Landén M et al. Cognitive manic symptoms associated with the P2RX7 gene in bipolar disorder. Bipolar Disord 2011; 13: 500-508
41. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R. SCAN: Schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 1990; 47: 589-593
42. Ryden E, Johansson C, Blennow K, Landen M. Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD. J Neural Transm 2009; 116: 1667-1674
43. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028-1042
44. Swartz KJ, Matson WR, MacGarvey U, Ryan EA, Beal MF. Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by highperformance liquid chromatography with fluorometric and coulometric electrode array detection. Anal Biochem 1990; 185: 363-376
45. Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE et al. Genevar: A database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010; 26: 2474-2476
46. Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet 2012; 8: E1002639
47. Nyholt DR. A simple correction for multiple testing for singlenucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769
48. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol 2008; 32: 361-369
49. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265
50. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
51. Schwieler L, Erhardt S, Nilsson L et al. Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons - possible involvement of endogenous kynurenic acid. Synapse 2006; 59: 290-298
52. Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G. Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci 2008; 83: 170-175
53. Banerjee J, Alkondon M, Pereira EF, Albuquerque EX. Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid. J Pharmacol Exp Ther 2012; 341: 500-509
54. Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012; 38: 426-432
55. Breton J, Avanzi N, Magagnin S, Covini N, Magistrelli G, Cozzi L et al. Functional characterization and mechanism of action of recombinant human kynurenine 3- hydroxylase. Eur J Biochem 2000; 267: 1092-1099
56. Holtze M, Saetre P, Engberg G, Schwieler L, Werge T, Andreassen OA et al. Kynurenine 3-monooxygenase polymorphisms: Relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. J Psychiatry Neurosci 2012; 37: 53-57
57. Aoyama N, Takahashi N, Saito S, Maeno N, Ishihara R, Ji X et al. Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population. Genes Brain Behav 2006; 5: 364-368
58. Holtze M, Saetre P, Erhardt S, Schwieler L, Werge T, Hansen T et al. Kynurenine 3- monooxygenase (KMO) polymorphisms in schizophrenia: An association study. Schizophr Res 2011; 127: 270-272
59. Ekelund J, Hennah W, Hiekkalinna T, Parker A, Meyer J, Lonnqvist J et al. Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol Psychiatry 2004; 9: 1037-1041
60. Hamshere ML, Bennett P, Williams N, Segurado R, Cardno A, Norton N et al. Genomewide linkage scan in schizoaffective disorder: Significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch Gen Psychiatry 2005; 62: 1081-1088
61. Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD et al. Convergent functional genomics of schizophrenia: From comprehensive understanding to genetic risk prediction. Mol Psychiatry 2012; 17: 887-905
62. Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H et al. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 2009; 14: 1069-1071
63. Kegel ME, Svensson CI, Erhardt S. IL-1b induces IDO and TDO transcription and provokes the release of kynurenic acid from human astrocytes in vitro. Abstract 240.19/E7, Neuroscience 2011
64. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006; 1073-1074: 25-37
65. Lappalainen T, Hannelius U, Salmela E, von Dobeln U, Lindgren CM, Huoponen K et al. Population structure in contemporary Sweden-A Y-chromosomal and mitochondrial DNA analysis. Ann Hum Genet 2009; 73: 61-73
66. Humphreys K, Grankvist A, Leu M, Hall P, Liu J, Ripatti S et al. The genetic structure of the Swedish population. PLoS One 2011; 6: E22547
67. Kocki T, Wielosz M, Turski WA, Urbanska EM. Enhancement of brain kynurenic acid production by anticonvulsants - Novel mechanism of antiepileptic activity? Eur J Pharmacol 2006; 541: 147-151
68. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 2006; 113: 1355-1365
69. Heyes MP, Chen CY, Major EO, Saito K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 1997; 326(Pt 2): 351-356
70. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3- dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005; 49: 15-23.